CLINICAL24 Forum: MRD in liquid biopsy - Tackling validation challenges and defining best practice
Thursday, November 5 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST
Molecular residual disease (MRD) testing through liquid biopsy enables unprecedented sensitivity of detecting cancer recurrence at sub 1% tumor DNA in the bloodstream. However, wider adoption depends on addressing complex challenges in analytical validation, standardization, reproducibility and routine laboratory implementation.
This expert roundtable will explore the current tumor-informed MRD testing landscape, including sensitivity, specificity, limits of detection and the balance between technical performance and real-world feasibility. Panelists will consider preanalytical variables, sample quality, low-frequency targets, data interpretation and workflow integration, alongside lessons from laboratories already implementing MRD testing.
The discussion will also examine the role of reference materials, controls, external quality assessment and metrological traceability in improving confidence and comparability across assays. Looking ahead, experts will assess emerging technologies, opportunities for consensus across laboratories, industry, quality organizations and regulators, and what best practice could look like over the next three to five years. Attendees will gain practical insights into the priorities required to strengthen performance, support reproducibility and advance responsible clinical adoption.
Certificate of Attendance
All attendees who join the live forum will automatically receive a certificate of attendance, including a summary of key learning outcomes, to support their continuing professional development.
If you watch the on-demand recording, you may request a certificate of attendance by emailing editor@selectscience.net.
Forum Details
• Cost: Free to attend
• Location: Online
• Duration: 60 minutes
• Format: Discussion format
Can't Attend Live?
Register to receive access to the recording after the event, allowing you to catch up on the discussion and revisit key insights at your convenience.
About CLINICAL24
CLINICAL24 is a global initiative dedicated to exploring the challenges facing modern clinical laboratories and highlighting the technologies, expertise, and collaborative approaches helping to improve patient care worldwide.
Speakers
Who should attend?
- Researchers in cancer diagnostics and liquid biopsy
- Lab Managers, lab supervisor/directors
- Molecular biologists
- Molecular diagnostics specialists
What will this webinar cover?
- Understand the current analytical landscape for MRD testing in liquid biopsy and the technical barriers to wider clinical adoption.
- Identify critical analytic validation considerations, including sensitivity, specificity, limits of detection, sample quality and low-frequency target detection.
- Evaluate the role of reference materials, controls, external quality assessment and metrological traceability in improving assay confidence and comparability.
- Recognize practical preanalytical, workflow and data interpretation challenges when implementing MRD testing in routine laboratories.
- Explore emerging technologies, opportunities for cross-sector consensus and priorities for defining best practice over the next three to five years.